Home Newsfeeds Northcoast Research Upgrades Toro to Buy

Northcoast Research Upgrades Toro to Buy

Northcoast Research analyst Tom Hayes upgrades Toro (NYSE:TTC) from Neutral to Buy.

byBenzinga Newsdesk

September 6, 2022

1 minute read

Northcoast Research analyst Tom Hayes upgrades Toro (NYSE:TTC) from Neutral to Buy.

UK’S National Institute for Health And Care Excellence Selects CEL-SCI’s Multikine As Potential New Standard of Care For Head & Neck Cancer

By Benzinga Newsdesk

December 4, 9:38 AM

CEL-SCI Corporation (NYSE:CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine* (Leukocyte Interleukin, Injection) to be evaluated as the potential

CVM

Boston Beer Company Gets A Spicy Buy Upgrade From Analyst Amid Other Beer Brands – Read Why

By Nabaparna Bhattacharya

May 14, 3:40 PM

Analyst upgrades Boston Beer Company to Buy, highlighting growth potential amid declining beer brands, while maintaining ratings for Constellation Brands and Molson Coors.

SAM

Bank of Hawaii Q3 EPS $1.28 Misses $1.43 Estimate, Sales $172.31M Miss $182.64M Estimate

By Benzinga Newsdesk

October 24, 6:49 AM

Bank of Hawaii (NYSE:BOH) reported quarterly earnings of $1.28 per share which missed the analyst consensus estimate of $1.43 by 10.49 percent. This is a 15.79 percent decrease over earnings of $1.52 per share from the

BOH

Beam Therapeutics’ Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy

By Vandana Singh

September 5, 1:58 PM

Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic

BEAM

Northcoast Research Upgrades Toro to Buy

Related Posts

UK’S National Institute for Health And Care Excellence Selects CEL-SCI’s Multikine As Potential New Standard of Care For Head & Neck Cancer

Boston Beer Company Gets A Spicy Buy Upgrade From Analyst Amid Other Beer Brands – Read Why

Bank of Hawaii Q3 EPS $1.28 Misses $1.43 Estimate, Sales $172.31M Miss $182.64M Estimate

Beam Therapeutics’ Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy